Compare ADMA Biologics Inc (ADMA) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Conagra Brands Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Conagra Brands Inc trades at $13.85 (market cap $6.71B). The key difference: Conagra Brands Inc is far larger — about 3.2× ADMA Biologics Inc's market cap, and Conagra Brands Inc pays a 9.98% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CAG | |
|---|---|---|
Market Cap | $2.13B | $6.71B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $20.65 |
52-Week Low | $7.60 | $12.58 |
Enterprise Value | $2.20B | $13.99B |
Dividend Yield | — | 9.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Conagra Brands (CAG) trades at $14.035, down 2.06% on the day, with mixed technical signals and a neutral overall stance. The stock shows modest valuation metrics with a P/E of 10.06 and P/B of 0.81, but faces profitability challenges with a negative net income margin of -0.39%. Recent earnings have been inconsistent, missing estimates in two of the last three quarters. A high dividend yield of approximately 10% is under scrutiny amid concerns over debt levels and slowing growth under new leadership, with the company set to report Q4 earnings on July 15, 2026.
The outlook for CAG is cautious, with potential upside from defensive positioning and dividend income, but significant risks from earnings volatility, high leverage, and dividend sustainability concerns. Investor sentiment is divided, with analysts predominantly neutral, reflecting uncertainty around the company's ability to navigate operational headwinds and debt management effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
